Abstract
Objectives To investigate factors affecting the long-term health behaviours and outcomes of headache patients and to design a risk-stratification tool.
Methods A population based observational-longitudinal cohort study using primary care electronic healthcare records from the UK Clinical Practice Research Datalink. 550,103 participants with a headache or migraine diagnosis of which 170,336 patients were identified as having recurrent headache-related events. Univariate and multivariable survival analysis was performed to determine factors influencing remission and a neural network classifier was developed.
Results There were almost twice as many female patients (352,330) as males (197,802). The median age at which a patient first saw their GP in males was 38 years, and in females was 37 years. Whilst age, gender and social deprivation significantly influenced the likelihood of seeing a GP, these factors had little effect on likelihood of remission from a period of recurrent headache-related events. In contrast, a comorbidity during the recurrent headache period reduced the risk of remission and increased median survival time from approximately 400-days up 1600. Increasing numbers of comorbidities progressively reduced the hazard risks for remission. The prediction models on remission within two and five years, demonstrated high precision and recall, with an F1 score of 0.795 and 0.887, respectively.
Interpretation Headache patients who suffer comorbidities have a substantively reduced likelihood of remission, highlighting an opportunity to considerably improve health outcomes in recurrent headache patients through addressing multi-morbidity more effectively. The prediction model could be used to help stratify patients most at risk of poor long-term outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We are grateful to the Oxford Science Innovation, NIHR Oxford Biomedical Research Centre and NIHR Oxford Health Biomedical Research Centre (Informatics and Digital Health theme, grant BRC-1215-20005) for funding. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. Alejo Nevado-Holgado declares support for the work through funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 826421. The funders did not have a role in any part of the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study design and data acquisition was approved by the UK Government's Independent Scientific Advisory Committee for MHRA database research (ISAC). Ethical approval was granted (ISAC project code 17_255R2).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Requests for access to the data reported in this paper will be considered by the corresponding author.
